Baltimore, MD (PRWEB) April 14, 2005
CBTEK, LLC and AT-GC BioPharm have entered into an agreement with respect to process development for development of instrumentation for detection of bio and chemical warfare agents. Under the agreement, AT-GC BioPharm will provide process development services for commercialization of chemical and biodetection using Py-GC-IMS.
CBTEK has licensed the technology from US Army and has been working with Edgewood Chemical and Biological Command (ECBC) at Aberdeen Proving Grounds, MD to commercialize the Py-GC-IMS technology for chemical and biological agent detection. "We believe Py-GC-IMS could be an integral part of the U.S. Government's biodefense arsenal," stated Arkesh Mehta, Ph.D., CEO of CBTEK. "AT-GC BioPharm has significant process development expertise and a proven track record of manufacturing other analytical instrumentation. We are pleased to be working with AT-GC BioPharm as we endeavor to meet all the requirements for potential procurement by the U.S. Government."
The specific milestones for the Py-GC-IMS commercial development program funded under the grant to be undertaken by AT-GC BioPharm include development of an automated quality control system (AQCS). Under the current agreement, AT-GC BioPharm will be developing the manufacturing process to enable large scale production requirements for licensure and, approved, commercial production for biodefense needs of the US government.
"We are excited to work with CBTEK on the Py-GC-IMS project," commented Harry Brubaker, Vice President for Business Development at AT-GC BioPharm. "We have extensive experience developing production capabilities for analytical instrumentation of all types, and we feel privileged to work on this important component of chemical and biological agent detection that could be a critical component of our national defense."
About CBTEK LLC.
CBTEK develops and commercializes hand held biological & chemical agent detectors for the public emergency services. This is a rapidly growing market in the US arising from the establishment of Âdomestic preparedness programsÂ in response to a Presidential directive. Police and fire departments would be the major users of these detection systems, as the first services on the scene when responding to chemical accidents or terrorist activities. The annual market for chemical agent detection equipment is expected to reach $150 million a year within the next five years, at an annual growth rate of 20%.
About AT-GC BioPharm
AT-GC BioPharm is a leader in applying proprietary Quality by DesignÂ technologies for the rapid manufacturing and optimization of novel biopharmaceutical products. The Company is directing its integrated portfolio of technologies to the process development and production of commercially valuable molecules with agricultural, biotechnological, chemical, industrial, and pharmaceutical applications. AT-GC BioPharm has established alliances and joint ventures with market leaders, such as Avanti Therapeutics, Blumberg & Associates, BPI Technologies. In addition, the Company has formed a broad strategic relationship with Avanti Therapeutics, a leading personalized medicine platform company. AT-GC BioPharm has commercialized products both independently and in collaboration with strategic partners and licensees. Additional information is available at AT-GC BioPharm's website: http://www.biopharm.at-gc.com.
Contact: Arkesh Mehta, Chief Executive Officer of CBTEK., +1-732-925-1597; or Jenny Smith, Corporate Communications of AT-GC BioPharm, +1-301-540-5474, email@example.com
# # #